Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results
Fate Therapeutics announced plans for a conference call on February 28, 2022, at 5:00 PM ET to discuss its fourth quarter and full year 2021 financial results and provide a corporate update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fate Therapeutics announced plans for a conference call on February 28, 2022, at 5:00 PM ET to discuss its fourth quarter and full year 2021 financial results and provide a corporate update. Interested parties can join via phone or through a live audio webcast accessible on the company's website. Fate Therapeutics specializes in programmed cellular immunotherapies for cancer, leveraging its proprietary induced pluripotent stem cell product platform to develop innovative NK and T-cell therapies.
Positive
- Company's leadership in the development of off-the-shelf cell products.
- Potential to synergize with existing cancer therapies.
Negative
- None.
Details
News Market Reaction – FATE
The recorded move for FATE in the trading session of this news was -4.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will host a conference call and live audio webcast on Monday, February 28, 2022 at 5:00 PM ET to report its fourth quarter and full year 2021 financial results and provide a corporate update.
In order to participate in the conference call, please dial (877) 303-6235 (domestic) or (631) 291-4837 (international) and refer to conference ID 1888465. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.